Astrazeneca Pharma India Ltd vs Mangalam Drugs And Organics Ltd Stock Comparison
Astrazeneca Pharma India Ltd vs Mangalam Drugs And Organics Ltd Stock Comparison
Last Updated on: May 07, 2026
Key Highlights
The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8535 as of 07 May 15:30
. The P/E Ratio of Astrazeneca Pharma India Ltd is 0 as of March 2024
.The P/E Ratio of Mangalam Drugs and Organics Ltd is 0 as of March 2024
. The Market Cap of Astrazeneca Pharma India Ltd is ₹ 0 crore as of March 2024
.The Market Cap of Mangalam Drugs and Organics Ltd is ₹ 146.65 crore as of March 2024
. The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Mangalam Drugs and Organics Ltd for the Dec '25 is ₹ 58.6 crore as compare to the Sep '25 revenue of ₹ 49.57 crore. This represent the growth of 18.22% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Mangalam Drugs and Organics Ltd for the Dec '25 is ₹ -1.32 crore as compare to the Sep '25 ebitda of ₹ -2.81 crore. This represent the decline of -53.02% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0%
The net profit of Mangalam Drugs and Organics Ltd changed from ₹ 2.68 crore to ₹ -9.84 crore over 7 quarters. This represents a CAGR of NaN%
The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Mangalam Drugs and Organics Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Astrazeneca Pharma India Ltd
AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology.
AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.
About Mangalam Drugs and Organics Ltd
Mangalam Drugs and Organics Limited was initially incorporated as 'Advent Pharma Private Limited' on April 18, 1972.
On July 1, 1997, the Company changed the name from Advent Pharma Private Limited to Mangalam Drugs and Organics Private Limited.
Thereafter, it converted the status into a Public Limited Company, changing the name to Mangalam Drugs and Organics Limited on August 10, 2001.
The company was established to set up a plant for manufacture of organic and inorganic chemicals.
The company is engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates.
The company has their manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra.
FAQs for the comparison of Astrazeneca Pharma India Ltd and Mangalam Drugs and Organics Ltd
Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Mangalam Drugs and Organics Ltd?
Market cap of Astrazeneca Pharma India Ltd is 21,338 Cr while Market cap of Mangalam Drugs and Organics Ltd is 47 Cr
What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Mangalam Drugs and Organics Ltd?
The stock performance of Astrazeneca Pharma India Ltd and Mangalam Drugs and Organics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Astrazeneca Pharma India Ltd and Mangalam Drugs and Organics Ltd?
As of May 7, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8535.3. On the other hand, Mangalam Drugs and Organics Ltd stock price is INR ₹30.09.
How do dividend payouts of Astrazeneca Pharma India Ltd and Mangalam Drugs and Organics Ltd compare?
To compare the dividend payouts of Astrazeneca Pharma India Ltd and Mangalam Drugs and Organics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.